Hexagon Bio, Inc.
Hexagon Bio is a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome. Leveraging a proprietary platform that combines data science, genomics, synthetic biology, and automation, the company mines microbial genomes for novel small molecules and their protein targets to develop therapeutics for human diseases, especially in oncology and infectious diseases. The company is advancing a pipeline of next-generation antibody-drug conjugates (ADCs) with novel payloads designed to address significant unmet needs in cancer treatment.
Industries
Nr. of Employees
medium (51-250)
Hexagon Bio, Inc.
Products
Preclinical ADC candidates using novel natural-product-derived payloads
A pipeline of preclinical antibody-drug conjugate (ADC) candidates that use small-molecule payloads discovered from microbial genomes, including payloads that inhibit protein translation and payloads with mechanisms orthogonal to existing ADC payloads.
Preclinical ADC candidates using novel natural-product-derived payloads
A pipeline of preclinical antibody-drug conjugate (ADC) candidates that use small-molecule payloads discovered from microbial genomes, including payloads that inhibit protein translation and payloads with mechanisms orthogonal to existing ADC payloads.
Services
Collaborative research partnerships to apply the company's platform (genomics, computation, synthetic biology, chemistry, automation) to discover and develop natural-product-derived small molecules.
Collaborative research partnerships to apply the company's platform (genomics, computation, synthetic biology, chemistry, automation) to discover and develop natural-product-derived small molecules.
Expertise Areas
- Metagenomic drug discovery
- Antibody-drug conjugate payload discovery
- Computational genomics and bioinformatics
- Machine learning for natural-product discovery
Key Technologies
- Next-generation sequencing
- Machine learning for bioinformatics
- Heterologous expression systems
- Synthetic biology
News & Updates
Hexagon Bio announced the appointment of Yujiro Hata to its Board of Directors.
Hexagon Bio raised $77.3 million in Series B financing to expand its discovery platform and advance microbial genome-derived small molecules.
Hexagon Bio raised $61 million to develop therapeutics mined from microbial genomes.
Hexagon Bio uses data science, genomics, synthetic biology, and automation to mine microbial genomes for therapeutics.
Scientists use bioinformatics and machine learning to find new compounds in fungal genomes for undruggable cancers and infections.
Hexagon uses genomic sequencing and AI to analyze fungi and uncover new drugs.
Hexagon Bio announced the appointment of Yujiro Hata to its Board of Directors.
Hexagon Bio raised $77.3 million in Series B financing to expand its discovery platform and advance microbial genome-derived small molecules.
Hexagon Bio raised $61 million to develop therapeutics mined from microbial genomes.
Hexagon Bio uses data science, genomics, synthetic biology, and automation to mine microbial genomes for therapeutics.
Scientists use bioinformatics and machine learning to find new compounds in fungal genomes for undruggable cancers and infections.
Hexagon uses genomic sequencing and AI to analyze fungi and uncover new drugs.